Home Newsfeeds Susquehanna Maintains Neutral on NetApp, Lowers Price Target to $65

Susquehanna Maintains Neutral on NetApp, Lowers Price Target to $65

Susquehanna analyst Mehdi Hosseini maintains NetApp (NASDAQ:NTAP) with a Neutral and lowers the price target from $75 to $65.

byBenzinga Newsdesk

November 30, 2022

1 minute read

Susquehanna analyst Mehdi Hosseini maintains NetApp (NASDAQ:NTAP) with a Neutral and lowers the price target from $75 to $65.

News
Tech

Palantir’s ‘Rock Concert’ AI Sales Strategy Is Rapidly Boosting Commercial Sales: ‘We Can’t Do Enough Of Them’

By Adam Eckert

April 25, 1:15 PM

Palantir doesn't go about selling its software products in conventional ways. After refusing to hire a sales team for years, the company is now using rock concert-like bootcamps to bring new customers on board.

PLTR

Astec Industries, Inc. Announces Michael Norris Will Now Serve As Materials Solutions Group President

By Benzinga Newsdesk

November 30, 5:20 PM

Astec Industries, Inc. (NASDAQ:ASTE) announced today that Michael Norris will now serve as Materials Solutions Group President. Mr. Norris joined Astec Industries in January of 2018 as VP International and currently

ASTE

Crucial Thursday: EUR/USD Traders Await Flowing Of Gas From Russia To Germany With Bated Breath

By Bhavik Nair

July 18, 3:30 AM

After breaching parity last week for the first time in twenty years, the downtrend in the EUR/USD pair has taken a pause but is still hovering around the lows ahead of a crucial Thursday when the gas flow from the Nord Stream pipe to Germany from Russia is supposed to resume.

OGZPY

Cyprium Therapeutics, A Fortress Biotech Subsidiary Company, Completes Asset Transfer Of CUTX-101 Copper Histidinate Product Candidate For Treatment Of Menkes Disease, To Sentynl Therapeutics, A Wholly-Owned Subsidiary Of Zydus Lifesciences Ltd.

By Benzinga Newsdesk

December 6, 9:41 AM

Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership over any FDA

FBIO

Susquehanna Maintains Neutral on NetApp, Lowers Price Target to $65

Related Posts

Palantir’s ‘Rock Concert’ AI Sales Strategy Is Rapidly Boosting Commercial Sales: ‘We Can’t Do Enough Of Them’

Astec Industries, Inc. Announces Michael Norris Will Now Serve As Materials Solutions Group President

Crucial Thursday: EUR/USD Traders Await Flowing Of Gas From Russia To Germany With Bated Breath

Cyprium Therapeutics, A Fortress Biotech Subsidiary Company, Completes Asset Transfer Of CUTX-101 Copper Histidinate Product Candidate For Treatment Of Menkes Disease, To Sentynl Therapeutics, A Wholly-Owned Subsidiary Of Zydus Lifesciences Ltd.